The COVID-19 pandemic reshaped the global economic landscape, triggering major disruptions in travel, hospitality, and manufacturing — but it also created new opportunities for certain companies. From healthcare innovators to tech platforms and online traders, some organisations experienced dramatic growth during the crisis. Here are five of the top companies that profited from the pandemic and why:

1. Quidel – Rapid Growth in Diagnostic Testing

Quidel, a California-based diagnostics company, saw its revenue jump by over 200% in 2020 as demand for COVID-19 tests surged. Its rapid antigen and molecular testing products became essential tools in public health responses, accounting for a significant portion of its income during the pandemic.

Why it profited:

• Quidel’s products were among the first to receive emergency use authorisation for COVID-19 testing.
• Mass demand from governments, healthcare providers, and testing centres drove sales worldwide.

2. Plus500 – Boom in Online Trading

Plus500, an online trading platform, reported a 146% increase in revenue between 2019 and 2020 as global markets became highly volatile due to the pandemic. Retail investors turned to online trading during lockdowns, leading to a surge in new accounts and trading activity.

Why it profited:

• Market volatility increased interest in assets and securities trading.
• Remote work and digital engagement made online trading more accessible to millions.

3. Peloton Interactive – At-Home Fitness Demand

Peloton, known for its connected fitness bikes and online subscription workouts, also benefited hugely from the pandemic. As gyms closed and people stayed home, Peloton’s revenue almost doubled in 2020.

Why it profited:

• Lockdowns accelerated the trend toward home workouts.
• Subscription-based fitness classes and connected exercise equipment became essential for health-conscious consumers.

4. BioNTech – mRNA Vaccine Innovation

BioNTech, the German biotechnology firm that partnered with Pfizer to develop one of the first widely deployed mRNA COVID-19 vaccines, saw exponential demand for its vaccine technology and intellectual property.

Why it profited:

• BioNTech’s vaccine enabled global immunisation campaigns.
• Long-term licensing, production, and continued demand contributed to strong financial performance.

5. Gilead Sciences – Remdesivir Sales

Gilead Sciences, a U.S. biotech company, generated billions in revenue from remdesivir, an antiviral drug that was among the first to receive emergency use approval for treating COVID-19. In 2021, remdesivir alone brought in more than $4.5 billion in annual sales.

Leave your comment on what other company you would add to the Top 10.